University of Texas System

Zhiqing Liu

Jia Zhou

Haitao Hu

Allan R Brasier

Xiaodong Cheng

Fang Mei

Bing Tian

Xiuzhen Fan

Na Ye

Fernanda Laezza

Erik Rytting

Haiying Chen

Syed Ali

Embodiments are directed to a series of novel EPAC antagonists that are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit ESI-09.

EPAC antagonists

Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.

Inhibitors of bromodomain-containing protein 4 (BRD4)

The invention relates generally to novel small molecule BRD4 modulators for HIV, the preparation thereof as well as the use thereof.

Small molecule BRD4 modulators for HIV epigenetic regulation

The present invention relates to novel small molecule modulators of Nav1.6 channels of the general formulae (I), (II), (III) and (IV), and the uses thereof. 

Fine-tune modulators of neuronal excitability for neuropsychiatric disorders

The invention relates generally to novel EPAC1 activators, such as Formula I and the preparation thereof as well as the use of EPAC1 activators as human immunodeficiency virus (HIV) latency reversal agents (LRAs). 

Growing community of inventors

Galveston, TX, United States of America

Zhiqing Liu